new glp-1 receptor agonists Revolutionizing obesity treatment: The emerging role of and next-generation pharmacotherapies New England Journalist of Medicine
Description
Semaglutide: A study compared liraglutide and semaglutide in terms of efficacy and side effects
Ongoing Research New studies are testing their impact on: Alzheimers disease Cardiovascular protection Inflammatory conditions These drugs might have more uses than we originally thought
For example, in December 2024, the FDA approved Zepbound for the treatment of sleep apnea
Mechanistic studies demonstrate these medications suppress neuroinflammation and improve pain processing in the brain
To put them into a practical protocol: Week 1 elimination phase
The following article appeared on February 21, 2025 on Law360 UK
